The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 368.00
Bid: 360.00
Ask: 374.00
Change: -8.00 (-2.13%)
Spread: 14.00 (3.889%)
Open: 375.00
High: 375.00
Low: 365.00
Prev. Close: 375.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Mar 2021 15:01

RNS Number : 0007S
MaxCyte, Inc.
11 March 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

MaxCyte, Inc.

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Baron Capital Group, Inc. ("BCG")BAMCO, Inc. ("BAMCO")Baron Capital Management, Inc. ("BCM")Ronald Baron

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

9/3/2021

6. Date on which issuer notified (DD/MM/YYYY):

10/3/2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.35%

Not applicable

3.35%

84,559,246

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

US57777K1060

2,835,954

Not applicable

3.35%

Not applicable

SUBTOTAL 8. A

2,835,954

3.35%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

New York, New York, U.S.A

Date of completion

10/3/2021

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFIEVIILLIL
Date   Source Headline
11th Jun 20187:00 amRNSMaxCyte & NIH enter CRADA for Sickle Cell Disease
21st May 20187:00 amRNSPreclinical Results at ASGCT Annual Meeting
30th Apr 20187:00 amRNSNotice of AGM and Annual Report
25th Apr 20187:00 amRNSCMO Appointment
4th Apr 20187:00 amRNSFinal Results for Year Ended 31 December 2017
15th Mar 20187:00 amRNSNotice of Full Year Results
28th Feb 20185:00 pmRNSDirector/PDMR Shareholding
15th Feb 20187:00 amRNSGrant of Options
13th Feb 20187:00 amRNSDr Richard Douglas Joins MaxCyte Board
1st Feb 20184:06 pmRNSBlock listing Interim Review
23rd Jan 20181:32 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSTrading Update
12th Jan 20185:13 pmRNSTotal Voting Rights
30th Nov 20173:26 pmRNSTotal Voting Rights
31st Oct 201712:47 pmRNSResult of AGM
16th Oct 20177:00 amRNSDeclaration of Audit Remuneration
5th Oct 20176:32 pmRNSHolding(s) in Company
5th Oct 20176:31 pmRNSHolding(s) in Company
28th Sep 20175:15 pmRNSNotice of AGM
19th Sep 20177:00 amRNSInterim Results
25th Aug 20177:00 amRNSNotice of Half Year Results
20th Jul 20176:02 pmRNSGrant of Options
12th Jul 20177:00 amRNSTrading Update
6th Jun 20177:00 amRNSResearch & Development Agreement with NIAID
31st May 20174:30 pmRNSTotal Voting Rights
2nd May 20171:42 pmRNSBlock Listing Application
25th Apr 20176:27 pmRNSHolding(s) in Company
25th Apr 20177:00 amRNSPresentation of Positive Preclinical Data
20th Apr 20176:00 pmRNSResult of Special Meeting and Issue of Equity
13th Apr 20171:00 pmRNSNotice of AGM and 2016 Annual Report and Accounts
31st Mar 201712:40 pmRNSResults of Placing
31st Mar 20177:00 amRNSProposed Placing to raise up to approx. £20.0m
20th Mar 20177:00 amRNSFull Year Results
14th Mar 20177:00 amRNSCRISPR THERAPEUTICS/CASEBIA COMMERCIAL LICENSE
2nd Mar 20177:00 amRNSMaxCyte to Present Pre-Clinical CARMA Data at AACR
1st Mar 20177:00 amRNSNotice of Full Year Results
24th Jan 20177:00 amRNSTrading Update
12th Jan 20177:00 amRNSStudy Published in Science Translational Medicine
3rd Jan 20172:49 pmRNSIssue of Equity from exercise of Share Options
21st Dec 20167:00 amRNSMaxCyte Announces Collaboration to Advance CARMA
6th Dec 20169:34 amRNSIssue of Equity from exercise of Share Options
27th Oct 20167:00 amRNSResult of Annual General Meeting
21st Oct 20167:43 amRNSDirector/PDMR Shareholding
28th Sep 20166:00 pmRNSGrant of Options
27th Sep 20167:00 amRNSFinancial Results for Six Months ended 30 June 16
19th Sep 20165:00 pmRNSNotice of AGM
6th Sep 20167:00 amRNSMaxCyte Bolsters Distributor Network in Asia
6th Sep 20167:00 amRNSNotice of Interim Results
12th Jul 20167:00 amRNSTrading Update
14th Jun 20167:00 amRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.